P/E ratio for Sonoma Pharmaceuticals (SNOA)
P/E ratio as of May 2024 (TTM): -0.1007
According to Sonoma Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.100724. At the end of 2022 the company had a P/E ratio of -0.4848.
P/E ratio history for Sonoma Pharmaceuticals from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.4848 | -71.4% |
| 2021 | -1.70 | -71.28% |
| 2020 | -5.90 | 316.96% |
| 2019 | -1.42 | 335.53% |
| 2018 | -0.3250 | -83.36% |
| 2017 | -1.95 | -176.35% |
| 2016 | 2.56 | -225.47% |
| 2015 | -2.04 | -131.37% |
| 2014 | 6.50 | -286.71% |
| 2013 | -3.48 | 1.07% |
| 2012 | -3.44 | -14.71% |
| 2011 | -4.04 | -30.7% |
| 2010 | -5.83 | 36.93% |
| 2009 | -4.26 | 289.87% |
| 2008 | -1.09 | -52.22% |
| 2007 | -2.28 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.81 | 4,680.21% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | 888.15% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.